Recombinant human follicle stimulating hormone versus human menopausal gonadotrophin induction: effects in mature follicle endocrinology.
To investigate follicular effects of recombinant human follicle stimulating hormone (rhFSH) induction on women with polycystic ovary syndrome (PCOS), steroid content was compared in mature follicles obtained using a long luteinizing hormone-releasing hormone agonist plus rhFSH or human menopausal gonadotrophin (HMG) in PCOS women and controls participating in an in-vitro fertilization programme. Follicular fluids (144 samples) were collected at oocyte retrieval by individual selective aspiration. Oocyte maturity and fecundability were assessed. Plasma and intrafollicular 17beta-oestradiol, progesterone, testosterone concentrations were assayed individually. No significant difference was seen in oocyte maturity and fecundability between PCOS and controls following rhFSH, or between PCOS rhFSH and HMG group. 17beta-oestradiol, testosterone and progesterone concentrations were lower in PCOS follicular fluid following rhFSH than HMG but the difference was not significant. Progesterone concentration, 17beta-oestradiol/progesterone, 17beta-oestradiol/testosterone were significantly different between the two induction groups, for PCOS fertilized oocyte follicles (P = 0.01, P < 0.05 and P < 0.05 respectively). Steroidogenic enzymatic activity seems to be regulated in healthy follicular cells in PCOS as well as in normal patients upon ovarian induction. Following rhFSH, higher PCOS follicular progesterone concentrations leading to a theoretically increased fecundability could suggest that recombinant FSH is a better inducer which needs to be confirmed.
Teissier
M P
MP
Centre d'Assistance Médicale à la Procréation, Service de Gynécologie-Obstétrique, Centre Hospitalier Universitaire de Limoges, France.
Chable
H
H
Paulhac
S
S
Aubard
Y
Y
D000328:Adult; D004958:Estradiol / Q000097:blood / Q000378:metabolism; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use*; D015571:Follicular Fluid / Q000378:metabolism; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy; D008297:Male; D008596:Menotropins / Q000627:therapeutic use*; D009865:Oocytes / Q000502:physiology; D006080:Ovarian Follicle / Q000503:physiopathology*; D010062:Ovulation Induction / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000503:physiopathology*; D011374:Progesterone / Q000097:blood / Q000378:metabolism; D011994:Recombinant Proteins / Q000627:therapeutic use; D013739:Testosterone / Q000097:blood / Q000378:metabolism
D011994:Recombinant Proteins; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol; D008596:Menotropins; D005640:Follicle Stimulating Hormone